| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f5ee29c39d7ed23ef72963d7212d338 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H10-00 |
| filingDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fce0c9fcdb4953eef16552a2701919e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84cd0dbe43d702d4f6902cda48a7880a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_123f32f74e8fbe8e57cd49802b23b289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ac63dca196290a80b67e1459b178d18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bacb2ab1a54977a16e3e846c75e5197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd1294bdfa9f176555141a8899d8690c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7195e019cf8772862bcff4c87a19fb20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7f2f32d013764d351124c4a0bb1eb31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13546aebb1ab1517b4af49e69d530c50 |
| publicationDate |
2020-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3618071-A1 |
| titleOfInvention |
Methods for selecting tumor-specific neoantigens |
| abstract |
Subjects having cancer can be treated in a personalized manner using a patient-specific cocktail of suitable neoantigen or neoepitope peptides and a pharmaceutically acceptable excipient. Selecting suitable neoantigens relies on certain properties of the patient-specific neoantigens predicted or evaluated based on information derived from databases which in turn are derived from prior measurements and observations. Such measurements and observations will be more or less precise and effected to some degree by errors. Thus, the information derived will also be effected by errors to a certain degree. Furthermore, a large number of different properties may need to be taken into account.In this situation, a selection method is suggested providing for an effective treatment at acceptable costs while reducing the influence of any errors in the underlying databases by binning certain descriptors of neoantigen properties and by improved ranking of the neonantigens according to the binning of the descriptors. |
| priorityDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |